New Bladder-Sparing combo aims to avoid surgery in cancer patients

NCT ID NCT07663747

Not yet recruiting Disease control Sponsor: The Netherlands Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a combination of two drugs—enfortumab vedotin (Padcev) and pembrolizumab (Keytruda)—can help people with muscle-invasive bladder cancer avoid bladder removal. About 56 participants will receive the drugs first, and those who respond well may get radiation or just observation instead of surgery. The goal is to see if this approach keeps the cancer away while preserving the bladder for at least two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda)
What this could lead to: If successful, this approach could allow many patients with bladder cancer to keep their bladder instead of having it removed, while still controlling the disease.
What could go wrong: This is an early phase 2 trial with only 56 participants, so results may not apply broadly. The combination therapy can cause significant side effects, and some patients may still need surgery or radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UROTHELIAL BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UROTHELIAL BLADDER CANCER

Contacts and locations

Locations

Antoni van Leeuwenhoek ziekenhuis

Amsterdam, Netherlands
Leiden University Medical Center Leiden (LUMC)

Leiden, Netherlands
University Medical Center Utrecht(UMCU)

Utrecht, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.